Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Tissue factor pathway inhibitor: an update of potential implications in the treatment of cardiovascular disorders
Autore:
Kaiser, B; Hoppensteadt, DA; Fareed, J;
Indirizzi:
Univ Jena, Ctr Vasc Biol & Med, D-99090 Erfurt, Germany Univ Jena ErfurtGermany D-99090 asc Biol & Med, D-99090 Erfurt, Germany
Titolo Testata:
EXPERT OPINION ON INVESTIGATIONAL DRUGS
fascicolo: 11, volume: 10, anno: 2001,
pagine: 1925 - 1935
SICI:
1354-3784(200111)10:11<1925:TFPIAU>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
DISSEMINATED INTRAVASCULAR COAGULATION; MOLECULAR-WEIGHT HEPARIN; CORONARY-ARTERY DISEASE; SMOOTH-MUSCLE CELLS; ACUTE MYOCARDIAL-INFARCTION; HUMAN ENDOTHELIAL-CELLS; FACTOR-FACTOR VIIA; UNFRACTIONATED HEPARIN; BLOOD-COAGULATION; ANTITHROMBIN-III;
Keywords:
cardiovascular diseases; clinical perspective; disseminated intravascular coagulation; heparins; sepsis; tissue factor; tissue factor pathway inhibitor;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
100
Recensione:
Indirizzi per estratti:
Indirizzo: Kaiser, B Univ Jena, Ctr Vasc Biol & Med, Nordhauser Str 78, D-99090 Erfurt, Germany Univ Jena Nordhauser Str 78 Erfurt Germany D-99090 urt, Germany
Citazione:
B. Kaiser et al., "Tissue factor pathway inhibitor: an update of potential implications in the treatment of cardiovascular disorders", EXPERT OP I, 10(11), 2001, pp. 1925-1935

Abstract

Tissue factor (TF) plays a crucial role in the pathogenesis of thrombotic,vascular and inflammatory disorders. Thus, the inhibition of this membraneprotein provides a unique therapeutic approach for prophylaxis and/or treatment of various diseases. Tissue factor pathway inhibitor (TFPI), the onlyendogenous inhibitor of the TF/Factor VIIa (FVIIa) complex, has recently been characterised biochemically and pharmacologically. Studies in patients demonstrated that both TF and TFPI may be indicators for the course and theoutcome of cardiovascular and other diseases. Based on experimental and clinical data, TFPI might become an important drug for several clinical indications. TFPI is expected to inhibit the development of post-injury intimal hyperplasia and thrombotic occlusion in atherosclerotic vessels as well as to be effective in acute coronary syndromes, such as unstable angina and myocardial infarction. Of special interest is the inhibition of TF-mediated processes in sepsis and disseminated intravascular coagulation (DIC), which are associated with the activation of various inflammatory pathways as wellas of the coagulation system. A Phase II trial of the efficacy of TFPI in patients with severe sepsis showed a mortality reduction in TFPI- compared to placebo-treated patients and an improvement of organ dysfunctions. TFPI can be administered exogenously in high doses to suppress TF-mediated effects, alternatively high amounts of TFPI can be released from intravascular stores by other drugs, such as heparin and low molecular weight heparins (LMWH). Using this method high concentrations of the inhibitor are provided atsites of tissue damage and ongoing thrombosis. At present, clinical studies with TFPI are rather limited so that the clinical potential of the drug cannot be assessed properly. However, TFPI and its variants are expected to undergo further development and to find indications in various clinical states.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/07/20 alle ore 19:00:56